Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877136 | 0.85 | AR (0.51) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL29297468 | 0.83 | AR (0.53) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL29296551 | 0.81 | NR1H2 (0.47) | CYP2C19 | |
| SCHEMBL29296675 | 0.78 | PTGDR2 (0.42) | CYP2C19 | |
| SCHEMBL29297728 | 0.78 | VCAM1 (0.42) | — | |
| SCHEMBL13211348 | 0.77 | AR (0.51) | ARPGRCYP2C19 | |
| SCHEMBL16379693 | 0.74 | AR (0.49) | ARPGR | |
| SCHEMBL30105299 | 0.74 | TRPV4 (0.50) | ARPGR | |
| SCHEMBL1762353 | 0.74 | TRPV4 (0.50) | ARPGR | |
| SCHEMBL17776383 | 0.73 | KIF11 (0.51) | ARPGRCYP2C19ABCB11ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | STANFORD RES INST INT (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | RNASEH1, RNASEL, DNASE1 | AR 4597/4885PGR 3539/4885CYP2C19 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.